Fig. 1 · Structure

Documents & Downloads

GSK256066

Cat. No. A11073 CAS 801312-28-7

PDE Inhibitor

GSK256066 is an exceptionally high affinity and selective inhibitor of PDE4 that inhibits PDE4 isoforms A-D with equal affinity and has a high HARBS (High-Affinity Rolipram Binding Site) ratio (>17).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PDE4B 3.2 pM

In Vitro Studies

GSK256066 significantly reduced baseline Nox2 activity in eosinophils from healthy subjects. In mouse IDG-SW3 osteoblast-to-late-osteocyte cells treated in OIM, GSK256066 significantly reduced intracellular and extracellular sclerostin levels compared with OIM controls. In neutrophils from healthy individuals, GSK256066 reduced Nox2 activity in the absence or presence of influenza or fMLP, whereas RSV exposure made neutrophils unresponsive to both PDE4 inhibitors. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Baseline oxidase activity in healthy human eosinophils

Cell-based study · eosinophils from healthy subjects (white; n = 8) [1]

In eosinophils from healthy subjects, pretreatment with GSK256066 significantly reduced baseline Nox2 activity relative to the normalized baseline value.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nox2 activityReported result Baseline Nox2 activity is significantly reduced by GSK256066 in eosinophils from healthy subjects[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 nmol/L
Exposure duration
30 minutes
Method
pretreated with PDE4 inhibitors
Vehicle
0.1% final DMSO concentration in the assays
Methods and source locations

Compound reported in the paper: GSK256066

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Compounds (S20, S21); MATERIALS AND METHODS > Assays > Amplex Red hydrogen peroxide assay (S22, S23); Figure 3 legend (S71, S75)

Nox2 activity: Nox2 activity; comparator: normalized baseline value — Figure 3 legend (S71)

Sclerostin levels in a mouse osteoblast-to-late-osteocyte cell line

Cell-based study · Mouse osteoblast-to-late-osteocyte cell line IDG-SW3 [2]

In a mouse osteoblast-to-late-osteocyte cell line cultured in OIM, GSK256066 significantly reduced intracellular and extracellular sclerostin levels compared with OIM controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
intracellular sclerostin concentrationReported result intracellular and extracellular levels of sclerostin were both significantly reduced in the presence of GSK256066[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.001‒1 μM
Exposure duration
21 days
Method
in OIM
Vehicle
DMSO
Co-treatment
Other interventions in this design: ascorbic acid 50 μg/mL; β-glycerophosphate 4 mM. Compound effect isolated by the comparison: compared to the OIM controls.
Methods and source locations

Compound reported in the paper: GSK256066

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.3. Intracellular and Extracellular Levels of Sclerostin in Mouse IDG-SW3 Cells (S39); 4. Materials and Methods > 4.1. Materials (S60); 4. Materials and Methods > 4.4. IDG-SW3 Cell Culture (S71, S73); Figure 5 legend (S106, S108); Figure 7 legend (S114)

intracellular sclerostin concentration: intracellular sclerostin concentration; comparator: OIM controls — 2. Results > 2.3. Intracellular and Extracellular Levels of Sclerostin in Mouse IDG-SW3 Cells (S39); Figure 5 legend (S106)

Oxidase activity in healthy human neutrophils

Cell-based study · Neutrophils from healthy individuals [1]

Neutrophils from healthy individuals showed a reduced Nox2 activity. Neutrophils were responsive to both PDE4 inhibitors, but RSV exposure eradicated inhibition by PDE4 inhibitors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nox2 activityReported result GSK256066 profoundly reduced Nox2 activity in neutrophils, in the absence or presence of influenza (P < .001) or fMLP, but RSV exposure made neutrophils unresponsive to both PDE4 inhibitors.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1.0 nmol/L
Exposure duration
30 minutes
Method
pretreated with PDE4 inhibitors
Vehicle
0.1% final DMSO concentration in the assays
Methods and source locations

Compound reported in the paper: GSK256066

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Compounds (S20, S21); MATERIALS AND METHODS > Assays > Amplex Red hydrogen peroxide assay (S22, S23); RESULTS > Effect of PDE4 inhibitors on Nox2 activity in virus‐exposed eosinophils and neutrophils (S59); Figure 3 legend (S74, S75)

Nox2 activity: Nox2 activity; comparator: normalized baseline value — RESULTS > Effect of PDE4 inhibitors on Nox2 activity in virus‐exposed eosinophils and neutrophils (S59)

In Vivo Studies

GSK256066 and indacaterol were dosed once daily in female C3H/HeN mice exposed to cigarette smoke. These treatments had no effect on pulmonary neutrophilia compared with vehicle-treated, smoke-exposed mice, as assessed by neutrophil numbers in BAL fluid. [3]

Pulmonary neutrophilia in smoke-exposed mice

Animal study · C3H/HeN female mice (n = 6–8) [3]

In female C3H/HeN mice exposed to cigarette smoke, GSK256066 and indacaterol dosed once daily had no effect on pulmonary neutrophilia compared with vehicle-treated, smoke-exposed mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
neutrophil numbers in the BAL fluidReported result GSK256066 (0.57 mg/kg) and indacaterol (0.43 mg/kg) dosed once daily had no effect on pulmonary neutrophilia[3]

Conditions shared by the study groups

Route
IT
Treatment course
dosed once daily; 1 h after compound dosing; 6 h per day over 3 weeks (5 day, 5 day, 4 day); Twenty four hours following the final exposure
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GSK256066 0.57 mg/kgvehicle-treated and smoke-exposed miceGSK256066 (0.57 mg/kg) and indacaterol (0.43 mg/kg) dosed once daily had no effect on pulmonary neutrophilia[3]
GSK256066 0.57 mg/kg
Model: C3H/HeN female mice (n = 6–8)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: GSK256066

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cigarette smoke-exposed C3H/HeN mice (S29, S30, S31); Results > Effect of GS-5759 in a cigarette smoke-induced model of pulmonary inflammation in mice (S75); Figure 3 legend (S111, S112)

neutrophil numbers in the BAL fluid: neutrophil numbers in the BAL fluid; comparator: vehicle-treated and smoke-exposed mice — Results > Effect of GS-5759 in a cigarette smoke-induced model of pulmonary inflammation in mice (S75); Figure 3 legend (S111)

GSK256066 0.57 mg/kg · Materials and Methods > Cigarette smoke-exposed C3H/HeN mice (S29, S30, S31); Results > Effect of GS-5759 in a cigarette smoke-induced model of pulmonary inflammation in mice (S75)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 801312-28-7
Applications PDE Inhibitor
Formula C27H26N4O5S
Molecular Weight 518.6
SMILES
CC1=C2C(=CC(=C1)S(=O)(=O)C3=CC=CC(=C3)C(=O)N(C)C)C(=C(C=N2)C(=O)N)NC4=CC(=CC=C4)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 4 mg/mL (7.71 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Sabogal Piñeros YS, Dekker T, Smids B, et al. Phosphodiesterase 4 inhibitors attenuate virus-induced activation of eosinophils from asthmatics without affecting virus binding. Pharmacol Res Perspect (2020). PMID: 32447834 DOI: 10.1002/prp2.557 Source material
  2. [2] Lee CC, Hung CM, Chen CH, et al. Novel Aptamer-Based Small-Molecule Drug Screening Assay to Identify Potential Sclerostin Inhibitors against Osteoporosis. Int J Mol Sci (2021). PMID: 34361085 DOI: 10.3390/ijms22158320 Source material
  3. [3] Salmon M, Tannheimer SL, Gentzler TT, et al. The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting β 2-adrenoceptor agonist in preclinical animal species. Pharmacol Res Perspect (2014). PMID: 25505595 DOI: 10.1002/prp2.46 Source material

Added to your cart

View Cart Checkout
Loading...